Precision Medicine Podcast · Trapelo

Bringing Precision Medicine—and Compassion—to Every Cancer Journey with Dr. Arif Kamal

·1 hr·3 clips
Kamal says survival can depend on “zip code,” then walks through a patient in Warrensburg, Missouri trying to reach a trial in Kansas City.
Karen Cushman opens Season 6 by going back to the American Cancer Society's origin story. She uses that history to show how far cancer care has come from the days when people rarely said the word cancer out loud. The episode frames precision medicine as a promise that still has to make its way into ordinary care. A guest joins to talk through what it actually takes to bring precision medicine to everyone. The conversation keeps moving between clinical progress and the everyday barriers that still keep patients from benefiting. Cushman points back to the ACS's founding in 1913 by 10 medical professionals and 5 business people. She also notes that the organization's work has helped contribute to a 33% drop in the overall cancer death rate in the U.S. From there, the show shifts from history to infrastructure. In 2021, ACS created its first Chief Patient Officer to bring its patient-facing work under one roof. That work includes navigation, education, lodging, transportation, and survivorship support across 5,000 communities nationwide. The guest describes this as a collaborative model, not a top-down one. ACS professionals meet with health systems, clinicians, and leaders to work through problems side by side. The goal is not to lecture institutions. It is to help solve the problems that keep precision medicine from reaching more patients. One example is precision diagnostics before treatment. If the root cause or fuel source of a cancer is not identified, the right therapy may never be chosen. The episode treats that gap as a solvable implementation problem. It comes down to getting the right test to the right patient at the right time. The guest explains that ACS can bring toolkits, make introductions, and connect teams that have already solved similar problems elsewhere. He also describes learning collaboratives that bring institutions together around a shared challenge and give them time, structure, and sometimes grant support to work through it together. The scale is large. On any given day, ACS is working with nearly 200 health systems on funded implementation science or quality improvement projects. The interview stays measured, but it never gets abstract. It keeps coming back to the patient cost of delay, confusion, and uneven access. The closing turn toward liquid biopsy widens the lens again. That technology is presented as part of an exciting, fast-moving oncology landscape. The episode's larger point is simple. Precision medicine has to be paired with compassion, logistics, and institutional follow-through if it is going to matter beyond the research page.

As heard by us

A sober, patient-centered look at precision medicine as access, not abstraction.

Precision medicine is treated here less like a slogan than like a logistics problem: who gets tested, who gets guided, and how cancer care becomes a little less punishing to navigate.

Read the full review in PlayNext →

Why you'd press play

If you want oncology explained through access, navigation, and real treatment decisions.

Read the full recommendation in PlayNext →
Listen to the show on